Evidence map›Paper›PMID 23885909›Full record

ReviewJournal of vascular and interventional radiology : JVIR2013

Personalized oncology in interventional radiology.

Nadine Abi-Jaoudeh, Austin G Duffy, Tim F Greten, Elise C Kohn, Timothy W I Clark, Bradford J Wood

Abstract readReview
In one paragraph

Review in Journal of vascular and interventional radiology : JVIR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Oncolytic virus immunotherapy: future prospects for oncology.Journal for immunotherapy of cancer · 2018
    Review
  7. Review
  8. White Paper on P4 Concepts for Pediatric Imaging.Journal of the American College of Radiology : JACR · 2016
    Article
  9. Review
  10. Review
  11. Interventional oncology: state of the art.La Radiologia medica · 2014
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nadine Abi-JaoudehRadiology and Imaging Sciences, National Institutes of Health, Rockville Pike, Bethesda, MD 20892, USA. naj@mail.nih.gov
Austin G Duffy
Tim F Greten
Elise C Kohn
Timothy W I Clark
Bradford J Wood

Funding

Clinical protocols for the treatment of GI cancerZIABC011343 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRETEN, TIM · 2010 to 2025
$4.8M
Navigation Tools for Image Guided Minimally invasive TherapiesZIACL040011 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
Intramural NIH HHS Z99 CL999999Intramural NIH HHS ZIA CL040011Intramural NIH HHS ZIA CL040015
6 · The paper itself

Abstract

As personalized medicine becomes more applicable to oncologic practice, image-guided biopsies will be integral for enabling predictive and pharmacodynamic molecular pathology. Interventional radiology has a key role in defining patient-specific management. Advances in diagnostic techniques, genomics, and proteomics enable a window into subcellular mechanisms driving hyperproliferation, metastatic capabilities, and tumor angiogenesis. A new era of personalized medicine has evolved whereby clinical decisions are adjusted according to a patient's molecular profile. Several mutations and key markers already have been introduced into standard oncologic practice. A broader understanding of personalized oncology will help interventionalists play a greater role in therapy selection and discovery.

Indexed as

Precision MedicineRadiography, InterventionalAntineoplastic AgentsBiomarkers, TumorGenetic Predisposition to DiseaseGenetic TestingGenomicsHumansImage-Guided BiopsyMedical OncologyMolecular Targeted TherapyNeoplasmsPatient SelectionPhenotypePredictive Value of TestsSignal TransductionAntineoplastic AgentsBiomarkers, Tumoradenosine triphosphateALKanalplastic lymphoma factorATPBCR-ABLBRAFbreakpoint cluster region/the Abelson tyrosineCD-20chronic myelogenous leukemiac-KITclusters of differentiation-20 (antigen of B-cells)CMLcolorectal carcinomaCRCechinoderm microtubule-associated protein-like 4EGFREML4epidermal growth factor receptorFDAFood and Drug AdministrationHCChepatocellular carcinomaHER-2human epidermal growth factor receptor-2Kirsten rat sarcoma viral oncogeneKRASmAbmammalian target of rapamycinmonoclonal antibodymTORnon–small cell lung carcinomaNSCLCPDGFRplatelet-derived growth factor receptorsmall molecule kinase inhibitorSMKItyrosine-protein kinase kit or mast/stem cell growth factor receptorvascular endothelial growth factorvascular endothelial growth factor receptor-2VEGFVEGFR2v-raf murine sarcoma viral oncogene

Identifiers

PMID23885909
PMCPMC3742380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.